Market News / Story
Clarity Pharmaceuticals Hits SECuRE Cohort Expansion Main Group Recruitment Target
Small Caps ·
Small Caps reports: Clarity Pharmaceuticals has reached the recruitment target for the Main Group of the Cohort Expansion in its Phase I/IIa SECuRE trial evaluating 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC). Sixteen participants have been enrolled in the Main Group and are being assessed for the efficacy and safety of up to six treatment cycles at a dose of 8 gigabecquerels (GBq). Recruitment is continuing for additional participants who will receive 8GBq…